LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Aandelen Lijst・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Gesloten

17.26 3.23

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

16.47

Max

17.52

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.4M -20M
Verkoop	-807K 71M
EPS	-0.13
Winstmarge	-28.24
Werknemers	624
EBITDA	-7.9M -14M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+19.35% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	121M 2.4B
Vorige openingsprijs	14.03
Vorige sluitingsprijs	17.26

Adaptive Biotechnologies Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 jun 2026, 23:49 UTC

Marktinformatie

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 jun 2026, 23:45 UTC

Acquisities, Fusies, Overnames

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 jun 2026, 23:44 UTC

Acquisities, Fusies, Overnames

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 jun 2026, 23:44 UTC

Acquisities, Fusies, Overnames

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 jun 2026, 23:43 UTC

Acquisities, Fusies, Overnames

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 jun 2026, 23:35 UTC

Marktinformatie

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 jun 2026, 22:06 UTC

Acquisities, Fusies, Overnames

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 jun 2026, 22:05 UTC

Acquisities, Fusies, Overnames

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 jun 2026, 22:05 UTC

Acquisities, Fusies, Overnames

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 jun 2026, 22:05 UTC

Acquisities, Fusies, Overnames

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 jun 2026, 20:51 UTC

Winsten

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jun 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jun 2026, 20:09 UTC

Marktinformatie

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 jun 2026, 19:36 UTC

Marktinformatie

Cattle Climbs as Crude Oil Falls -- Market Talk

9 jun 2026, 19:32 UTC

Marktinformatie

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 jun 2026, 19:25 UTC

Marktinformatie

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 jun 2026, 19:00 UTC

Marktinformatie

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 jun 2026, 18:52 UTC

Acquisities, Fusies, Overnames

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 jun 2026, 18:47 UTC

Marktinformatie

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 jun 2026, 18:37 UTC

Marktinformatie

Canada's Cooling Trade With the U.S. -- Market Talk

9 jun 2026, 18:27 UTC

Marktinformatie

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 jun 2026, 17:35 UTC

Marktinformatie

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 jun 2026, 17:30 UTC

Marktinformatie

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 jun 2026, 16:34 UTC

Marktinformatie

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 jun 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jun 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jun 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

9 jun 2026, 15:28 UTC

Marktinformatie

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 jun 2026, 15:25 UTC

Marktinformatie

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Peer Vergelijking

Prijswijziging

Adaptive Biotechnologies Corp Prognose

Koersdoel

By TipRanks

19.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20.17 USD 19.35%

Hoogste 22 USD

Laagste 18 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Adaptive Biotechnologies Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Adaptive Biotechnologies Corp - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.